Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTC21C in IgA Nephropathy
NCT06774664Phase 2Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Jan 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SCTC21C in IgA nephropathy (IgAN), sponsored by Sinocelltech Group Limited. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
SCTC21C
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06774664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774664.